Literature DB >> 27277844

Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo.

Chin-Cheng Su1, Tsung-Lang Chiu2.   

Abstract

Tan-IIA exerts powerful inhibitory effects in gastric cancer AGS cells. The PI3K/AKT/mTOR pathway is one of the most frequently dysregulated kinase cascades in human cancer. In the present study, we investigated the protein expression levels of PI3K, AKT and mTOR in AGS cells treated with Tan-IIA both in vitro and in vivo. The AGS cells were treated with Tan-IIA for different durations in vitro. In the in vivo study, AGS cell xerograft SCID mice were treated with Tan-IIA for 8 weeks. Subsequently, the protein expression of EGFR, IGFR, PI3K, AKT and mTOR was measured by western blotting. The results showed that Tan-IIA was able to decrease the protein expression levels of EGFR, IGFR, PI3K, AKT and mTOR significantly and dose-dependently in vitro and in vivo. In conclusion, these findings indicate Tan-IIA could inhibit AGS cells through decreasing the protein expression of EGFR, IGFR and blocking PI3K/AKT/mTOR pathway both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27277844     DOI: 10.3892/or.2016.4857

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway.

Authors:  Zhen Lu; Aman Xu; Xiao Yuan; Kaiwei Chen; Likun Wang; Tao Guo
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

2.  Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways.

Authors:  Yingchun Zhu; Qiqiang Tang; Guopin Wang; Ruodong Han
Journal:  Curr Neurovasc Res       Date:  2017       Impact factor: 1.990

3.  Role of ARPC2 in Human Gastric Cancer.

Authors:  Jun Zhang; Yi Liu; Chang-Jun Yu; Fu Dai; Jie Xiong; Hong-Jun Li; Zheng-Sheng Wu; Rui Ding; Hong Wang
Journal:  Mediators Inflamm       Date:  2017-06-13       Impact factor: 4.711

4.  Tanshinone‑IIA attenuates the deleterious effects of oxidative stress in osteoporosis through the NF‑κB signaling pathway.

Authors:  Shaowen Zhu; Wanfu Wei; Zhiwei Liu; Yang Yang; Haobo Jia
Journal:  Mol Med Rep       Date:  2018-03-14       Impact factor: 2.952

5.  The anticancer mechanism investigation of Tanshinone IIA by pharmacological clustering in protein network.

Authors:  Yan-Feng Cao; Shi-Feng Wang; Xi Li; Yan-Ling Zhang; Yan-Jiang Qiao
Journal:  BMC Syst Biol       Date:  2018-10-29

6.  LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2.

Authors:  Jian Lu; Min Chen; Sumeng Gao; Jigang Yuan; Zhu Zhu; Xiaoping Zou
Journal:  Oncol Lett       Date:  2018-01-23       Impact factor: 2.967

7.  The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.

Authors:  Chao Lv; Hua-Wu Zeng; Jin-Xin Wang; Xing Yuan; Chuang Zhang; Ting Fang; Pei-Ming Yang; Tong Wu; Yu-Dong Zhou; Dale G Nagle; Wei-Dong Zhang
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

8.  Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells.

Authors:  Chien-Ming Chiu; Sung-Ying Huang; Shu-Fang Chang; Kuan-Fu Liao; Sheng-Chun Chiu
Journal:  Onco Targets Ther       Date:  2018-03-29       Impact factor: 4.147

9.  MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma.

Authors:  Jiale Zhang; Jie Zhang; Wenjin Qiu; Jian Zhang; Yangyang Li; Enjun Kong; Ailin Lu; Jia Xu; Xiaoming Lu
Journal:  J Neurooncol       Date:  2018-05-17       Impact factor: 4.130

Review 10.  The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients.

Authors:  Li Fu; Bing Han; Yang Zhou; Jie Ren; Wenzhi Cao; Gopal Patel; Guoyin Kai; Jun Zhang
Journal:  Front Pharmacol       Date:  2020-03-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.